Putting heparin into perspective: Its history and the evolution of its use during Percutaneous Coronary Interventions

Journal of Invasive Cardiology

Volumn 12, Issue SUPPL. F, 2000, Pages

  Kleiman, Neal S ^a   Weitz, Jeffrey I ^b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN;

ARTICLE; CORONARY ARTERY DISEASE; DRUG SCREENING; HEART CATHETERIZATION; HISTORY; HUMAN; METHODOLOGY; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CORONARY DISEASE; DRUG EVALUATION; HEART CATHETERIZATION; HEPARIN; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS;

EID: 0034573396     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Gruentzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis. N Engl J Med 1979;301:61-68.
2. Howell WH. The role of antithrombin and thromboplastin (thromboplastic substance) in the coagulation of the blood. Am J Physiol 1911;29:187.
3. Howell WH. The factors concerned in the process of the clotting of blood. Ther Gaz 1912;36:95.
4. McLean J. The discovery of heparin. Circulation 1959;19:75.
5. Marcum JA. The discovery of heparin revisited: The peptone connection. Perspect Biol Med 1996;39:610-625.
6. Crafoord C. Preliminary report on post-operative treatment with heparin as a preventive of thrombosis. Acta Chir Scand 1937;79:407-426.
7. Murray DWG. Heparin and thrombosis of veins following injury. Surgery 1937;2:163-187.
8. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 1998;114:489S-510S.
9. Tollefsen DM. Heparin cofactor II. Adv Exp Med Biol 1997;425:35-44.
10. Abildgaard U. Heparin/low-molecular-weight heparin and tissue factor pathway inhibitor. Haemostasis 1993;23(Suppl 1):103-106.
11. Olsson P, Lagergren H, Ek S. The elimination from plasma of intravenous heparin. Acta Med Scand 1963;173:619-630.
12. Mascelli MA, Kleiman NS, Marciniak SJ Jr., et al. Therapeutic heparin concentrations augment platelet reactivity: Implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab [In Process Citation]. Am Heart J 2000;139:696-703.
13. Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia. Diagnosis, natural history, and treatment options. Postgrad Med 1998;103:169-178.
14. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-391.
15. Baker BA, Adelman MD, Smith PA. Inability of the activated partial thromboplastin time to predict heparin levels. Arch Intern Med 1997;157:2475-2479.
16. Hirsh J. Heparin. N Engl J Med 1991;324:1565-1574.
17. Dougherty KG, Gaos CM, Bush HS, et al. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cathet Cardiovasc Diagn 1992;26:260-263.
18. Avendano A, Ferguson JJ. Comparison of Hemochron and Hemo-Tec activated coagulation time target values during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994;23:907-910.
19. Ogilby JD, Kopelman HA, Klein LW, Agarwal JB. Adequate heparinization during PTCA: Assessment using activated clotting times. Cathet Cardiovasc Diagn 1989;18:206-209.
20. Pesola GR, Pesola DA. Heparin dosing for percutaneous coronary angioplasty: Use of body surface area to improve initial activated clotting time values. Clin Cardiol 1997;20:1006-1009.
21. Ferguson JJ, Fathy Waly HM, Le D, et al. The effect of body weight and body surface area correction on the distribution of the ACT response to bolus doses of heparin for PTCA. J Invas Cardiol 1998;10:318-322.
22. Franke JG, Mildenberger RR, Mackenzie GW, et al. (unknown). NY Acad Sci 1989;556:447-449.
23. Wilson JM, Dougherty KG, Ellis KO, Ferguson JJ. Activated clotting times in acute coronary syndromes and percutaneous transluminal coronary angioplasty. Cathet Cardiovasc Diagn 1995;34:1-5.
24. Khan M, Sepulveda B, French BA, et al. Rebound increase in thrombin activity with associated decrease in Antithrombin III levels after PTCA. Circulation 1995;92:785A.
25. Bittl JA, Strony J, Brinker JA, et al., for the Hirulog Angioplasty Investigators. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995;333:764-769.
26. Heras M, Cheseboro JH, Penny WJ, et al. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Circulation 1989;79:657-665.
27. Heras M, Cheseboro JH, Penny WJ, et al. Importance of adequate heparin dosage in arterial angioplasty. Circulation 1988;78:654-660.
28. Lacoste LL, Lam JYT, Bilodeau L, et al. Is antithrombotic therapy with heparin during PTCA effective? J Am Coll Cardiol 1992;19:231A.
29. Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 1975;69:674-684.
30. Young JA, Kisker CT, Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg 1978;26:231-240.
31. Popma JJ, Weitz J, Bittl JA, et al. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 1998;114:7288-7415.
32. Juran NB, Smith DD, Rouse CL, et al. Survey of current practice patterns for percutaneous transluminal coronary angioplasty. SANDBAG Nursing Coordinators. Am J Crit Care 1996;5:442-448.
33. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
34. Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. Circulation 1995;91:2882-2890.
35. Lincoff AM, Tcheng JE, Califf RM, et al. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. Am J Cardiol 1997;79:286-291.
36. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
37. Moliterno DJ, Califf RM, Aguirre FV, et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 1995;75:559-562.
38. Ammar T, Scudder LE, Coller BS. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist C7e3 fab on the activated clotting time. Circulation 1997;95:614-617.
39. Kleiman NS, Lincoff AM, Kereiakes DJ, et al. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: Evidence for a complex interaction in a multicenter trial. Circulation 1998;97:1912-1920.
40. Marso SP, Lincoff AM, Ellis SG, et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) diabetic substudy. Circulation 1999;100:2477-2484.
41. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 1999;99:2720-2732.
42. Narins CR, Hillegass WB Jr., Nelson CL, et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996;93:667-671.
43. Ferguson JJ, Dougherty KG, Gaos CM, et al. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994;23:1061-1065.
44. McGarry TF. The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J 1992;123:1445-1451.
45. Bittl JA, Ahmed WH. Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty. Am J Cardiol 1998;82:50P-6P.
46. Chew DP, Bhatt DL, Lincoff AM, et al. Defining the optimal ACT during percutaneous coronary intervention: Aggregate results from six randomized controlled trials (Abstr). Circulation 2000;(special supplement):in press.
47. Vainer J, Fleisch M, Gunnes P, et al. Low-dose heparin for routine coronary angioplasty and stenting. Am J Cardiol 1996;78:964-966.
48. Boccara A, Benamer H, Juliard JM, et al. A randomized trial of a fixed high dose vs. a weight-adjusted low dose of intravenous heparin during coronary angioplasty. Eur Heart J 1997;18:631-635.
49. Kong DF, Califf RM. Post-procedure heparin: Boon or burden? Am Heart J 1998;136:183-185.
50. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q wave coronary events study group. N Engl J Med 1997;337:447-452.
51. Antman EM. TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q wave myocardial infarction: A double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators. Am Heart J 1998;135:S353-S360.
52. Karsch KR, Preisack MB, Baildon R, et al. Low-molecular-weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of restenosis after PTCA, early administration of reviparin in a double-blind unfractionated heparin and placebo-controlled evaluation. J Am Coll Cardiol 1996;28:1437-1443.
53. Kereiakes DJ, Fry E, Matthai W, et al. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first". J Invas Cardiol 2000;12(Suppl A):1A-5A.
54. Curran MJ, Grines CL. Use of low-molecular-weight heparin in percutaneous intervention. J Invas Cardiol 2000;12(Suppl C):13C-7C.
55. Kereiakes DJ, Michelson AD, Kruger LA, et al. Leukocyte-platelet aggregation, platelet activation and GP IIb/IIIa expression following PCI: Effects of dalteparin or UFH in combination with abciximab. Abstract submitted to ACC 2000.